Titre :

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT.

Auteur(s) :

Czerw, T. [Auteur]
Iacobelli, S. [Auteur]
Malpassuti, V. [Auteur]
Koster, L. [Auteur]
Kröger, N. [Auteur]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Maertens, J. [Auteur]
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Watz, E. [Auteur]
Poiré, X. [Auteur]
Snowden, J. A. [Auteur]
Kuball, J. [Auteur]
Kinsella, F. [Auteur]
Blaise, D. [Auteur]
Institut Paoli-Calmettes [IPC]
Reményi, P. [Auteur]
Mear, J. B. [Auteur]
Centre Hospitalier Universitaire [Rennes]
Cammenga, J. [Auteur]
Rubio, Marie Thérèse [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Maury, Sebastien [Auteur]
Hôpital Henri Mondor
Daguindau, E. [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Finnegan, D. [Auteur]
Hayden, P. [Auteur]
Hernández-Boluda, J. C. [Auteur]
Mclornan, D. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Date de publication :

2021-12-04

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The optimal CD34 + cell dose in the setting of RIC allo-HCT for myelofibrosis (MF) remains unknown. We retrospectively analyzed 657 patients with primary or secondary MF transplanted with use of peripheral blood (PB) stem ...
Lire la suite >The optimal CD34 + cell dose in the setting of RIC allo-HCT for myelofibrosis (MF) remains unknown. We retrospectively analyzed 657 patients with primary or secondary MF transplanted with use of peripheral blood (PB) stem cells after fludarabine/melphalan or fludarabine/busulfan RIC regimen. Median patient age was 58 (range, 22–76) years. Donors were HLA-identical sibling (MSD) or unrelated (UD). Median follow-up was 46 (2–194) months. Patients transplanted with higher doses of CD34 + cells (>7.0 × 106/kg), had an increased chance of achievement of both neutrophil (hazard ratio (HR), 1.46; P < 0.001) and platelet engraftment (HR, 1.43; P < 0.001). In a model with interaction, for patients transplanted from a MSD, higher CD34 + dose was associated with improved overall survival (HR, 0.63; P = 0.04) and relapse-free survival (HR, 0.61; P = 0.02), lower risk of non-relapse mortality (HR, 0.57; P = 0.04) and higher rate of platelet engraftment. The combined effect of higher cell dose and UD was apparent only for higher neutrophil and platelet recovery rate. We did not document any detrimental effect of high CD34 + dose on transplant outcomes. More bulky splenomegaly was an adverse factor for survival, engraftment and NRM. Our analysis suggests a potential benefit for MF patients undergoing RIC PB-allo-HCT receiving more than 7.0 × 106/kg CD34 + cells.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T05:33:11Z
2024-03-01T13:50:13Z